May 7, 2008
Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
Toronto, ON - Apotex Inc., Canada’s largest generic pharmaceutical company has successfully bid and been awarded a tender from the Rwandan Government for the life saving triple combination AIDS drug "Apo Triavir". Apotex is the first company to provide this medicine to Africa under the provisions of the Canadian Access to Medicines Regime (CAMR). 

May 1, 2008
Biosimilar G-CSF: Cooperation on Three Continents.
Toronto, ON - A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL) of India. Neukine®, a recombinant granulocyte colony stimulating factor (G-CSF) is already manufactured and marketed in India and other countries by IBPL. 

December 5, 2007
Apotex, Canada’s Largest Generic Pharmaceutical Company Makes 2nd Acquisition in Europe by Purchasing Lareq Pharma of Spain
Toronto, ON - Apotex Inc., announced today that it has acquired Lareq Pharma S.L. of Spain for an undisclosed sum from Industria Quimica Y Farmaceutica VIR S.A.

November 15, 2007
The Largest Canadian-Owned Generic Pharmaceutical Company Acquires Topgen E.S.V. in Belgium from Zambon
Toronto, ON - Apotex Inc., the largest Canadian-owned generic company announced today the purchase from Zambon of the pharmaceutical company, Topgen, E.S.V. of Belgium, No acquisition price was disclosed.

September 20, 2007
Life Saving AIDS Drug for Africa Gets Final Clearance
Toronto, ON – The Federal Commissioner of Patents issued today a compulsory licence for ApoTriavir under Canada’s Access to Medicines Regime Program (CAMR) allowing Apotex to proceed with manufacturing of the product. This drug, a triple combination AIDS therapy, was the first product to be approved by Health Canada under the provisions of the CAMR....

August 29, 2007
Barr’s Portia® Generic Oral Contraceptive Approved and Launched in Canada
Woodcliff Lake, NJ – Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc., has received approval from the Therapeutic Products Directorate (TPD) of Health Canada for its Abbreviated New Drug Submission (ANDS) for its Portia® generic oral contraceptive as a generic equivalent of Wyeth Laboratories’ Min-Ovral® Tablets....

July 31, 2007
Experts in Thalassemia Convene in Cyprus
U.K. Thalassemia Society, LONDON, UK – World experts in thalassemia convened in Paphos to discuss recent findings of decreased heart disease and increased survival in patients with the inherited disease, thalassemia major. Cyprus has one of the highest recorded carrier rates for this genetic disease, a disorder in which children require blood transfusions every 2-4 weeks to survive....

May 24, 2007
Apotex Launches Generic Norvasc®
WESTON, FLORIDA, U.S.A. – Apotex Corp. announced today that it has launched amlodipine besylate tablets (2.5 mg, 5 mg, and 10 mg), the generic equivalent of Pfizer’s Norvasc®. The launch follows Monday’s issuance of the mandate by the US Court of Appeals for the Federal Circuit’s decision of March 22 invalidating Pfizer’s US Patent 4,879,303 (the ‘303 patent) covering amlodipine besylate...

March 21, 2007
Apotex Invalidates Norvasc® Patent
WESTON, FLORIDA, U.S.A. – Apotex Corp. announced today the Federal Circuit Court of Appeals in the case of Pfizer, Inc. v. Apotex, Inc. reversed a trial court’s ruling and found that Pfizer’s U.S. Patent 4,879,303 (the ‘303 patent) covering the Pfizer product Norvasc® was invalid...

August 31, 2006
Court Halts Sales of Generic Plavix®
WESTON, FLORIDA, U.S.A. – Apotex Corp. today announced that the U.S. District Court of the Southern District of New York has granted the request of Bristol Myers Squibb and Sanofi to issue a preliminary injunction to prevent further sales of Apotex’s generic version of Sanofi’s Plavix® (clopidogrel 75mg tablets)...

August 8, 2006
Apotex Launches First Generic Plavix®
WESTON, FLORIDA, U.S.A. – Apotex Corp. announced that it has today launched clopidogrel bisulfate 75 mg tablets. Clopidogrel is the generic equivalent of Sanofi's Plavix®, which is marketed in the U.S. by Bristol Myers Squibb....

January 25, 2006
Apotex Receives Approval for First Generic Plavix®
WESTON, FLORIDA, U.S.A. – Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel bisulfate 75 mg tablets...

March 14, 2005
Apotex Etobicoke Expansion Project was Chosen As One The 5 Finalists for the 2005 global award for the "Facility of The Year"
TORONTO, ONTARIO, CANADA – The Apotex Etobicoke Expansion Project has been chosen as one of 5 finalists for the 2005 global award for “Facility Of The Year” by ISPE (International Society of Pharmaceutical Engineering), INTERPHEX and Pharmaceutical Processing...

February 21, 2005
$3 Million Gift to Help Establish Cutting Edge Facility for Faculty of Pharmacy
WINNIPEG, MANITOBA, CANADA– Apotex Inc. has pledged $3 million to assist the Faculty of Pharmacy create a new teaching and research facility on the University of Manitoba's Bannatyne campus. In recognition of this gift, the building will be called the Apotex Centre...

January 5, 2005
Canadian Pharma Company Sets Bar For Company Donating For Tsunami Relief Efforts
TORONTO, ONTARIO, CANADA– Apotex Inc., the largest Canadian-owned pharmaceutical company is assisting in the Tsunami Relief efforts in two clear ways....

December 14, 2004
$2 Million Donated to Faculty of Pharmacy at U of T
TORONTO, ONTARIO, CANADA– Canadian pharmaceutical leader Apotex Inc. has pledged another $2-million in addition to its original $5-million donation towards the new Leslie L. Dan Pharmacy Building at the University of Toronto...

November 9, 2004
Apotex Announce Largest Pharmaceutical Investment in Canadian History - $627 Million Expansion Has Created 1,500 Jobs
TORONTO, ONTARIO, CANADA – Apotex today announced the completion of the largest pharmaceutical investment in Canadian history. The announcement coincided with the opening of a new state-of-the art research and development and manufacturing facility, and major expansions at three of the firm’s other high-tech operations...
Watch the Video  (10 MB, Windows Media)

November 9, 2004
McGuinty Government Welcomes 1,500 New Jobs
OFFICE OF THE PREMIER, TORONTO – Ontario Premier Dalton McGuinty today celebrated the official opening of four new Apotex pharmaceutical facilities in Ontario. The facilities represent the largest pharmaceutical investment in Canadian history and create 1,500 new jobs...

April 26, 2004
Apotex Victory in Generic Paxil® Confirmed - Federal Circuit Court of Appeals Affirms District Court’s Judgment in Favor of Apotex.
WESTON, FLORIDA, U.S.A. – Apotex Corp. today praised the decision of the U.S. Court of Appeals for the Federal Circuit holding that GlaxoSmithKline’s U.S. Patent No. 4,721,723 (the '723 patent), covering the antidepressant Paxil® (paroxetine hydrochloride), is invalid...

January 29, 2004
Generic Pharmaceutical Leader Strengthens Innovative Drug Research By Creating New Company Called “ApoPharma Inc.”
TORONTO, ONTARIO, CANADA – The Apotex Group of Companies, a world leader in the development of generic pharmaceuticals, announced today the reorganization of its innovative drug division into a new company called “ApoPharma Inc.”,....

December 18, 2003
European Court Rules Against Blood Doctor, Nancy Olivieri, in her Challenge of the Marketing Authorization of Ferriprox® (Deferiprone). Decision Ensures Patient Access To Life-Saving Treatment
LUXEMBOURG – The Court of Justice of the European Communities, Court of First Instance dismissed as inadmissible the case brought by Dr. Nancy Olivieri against the European Commission (EC) challenging its marketing approval for Ferriprox® (deferiprone)....

November 7, 2003
Canadian-Owned Generic Company Prepared To Provide HIV/AIDS Drug to Developing Nations
TORONTO, ONTARIO, CANADA– The Apotex Group of Companies announced today that it is prepared to 
produce a key HIV/AIDS drug under legislation introduced yesterday to allow Canadian-made generic pharmaceuticalsto be exported to developing countries...

November 3, 2003
The Apotex Group Donates $1.5 Million To Laval University's Faculty of Pharmacy
QUEBEC CITY, CANADA– The Apotex Group today announced a $1.5 million donation to Laval University’s 
Faculty of Pharmacy. The university and representatives of the pharmaceutical company who attended the event were 
extremely enthusiastic about the announced...

September 22, 2003
Study Confirms Safety and Efficacy of Deferiprone
TORONTO, ONTARIO, CANADA– A new study published in Blood reports impressive results from a large, long-term prospective study examining the safety and efficacy of deferiprone, an orally active medicine for the treatment of iron overload in thalassemia, a rare genetic blood disorder...

September 8, 2003
Apotex Launches First Generic Version of Paxil® - Affordable Product Kept from Consumers for Years Too Long!
WESTON, FLORIDA, U.S.A.– Apotex Corp. today announced that it has launched paroxetine hydrochloride tablets, 10mg, 20mg, 30mg and 40mg. The U.S. Food and Drug Administration has determined that Apotex’ paroxetine tablets are therapeutically equivalent to GlaxoSmithKline’s (GSK) Paxil®...

July 15, 2003
Generic Company #1 In Canadian Pharmaceutical Industry For Research & Development Spending
TORONTO, ONTARIO, CANADA – The Apotex Group, the largest Canadian owned pharmaceutical company headquartered in Toronto, has moved into the #1 position in Canada for research and development spending in the pharmaceutical industry...

July 4, 2003
Canada's Top 100 Corporate R&D Spenders List 2003
Canada's Corporate Innovation Leaders - A supplement prepared by Research Infosource Inc...

May 7, 2003
New Hope For Patients Afflicted with Rare Genetic Blood Disease: Study Finds Deferiprone Provides Significantly Greater Cardiac Protection
TORONTO, ONTARIO, CANADA – Iron-induced heart disease is the major cause of death in patients with the genetic blood disorder, thalassemia. Now, a new published study in the journal Haematologica, reveals that long-term therapy with deferiprone (Ferriprox™) provides greater protection of the heart from iron overload than standard therapy...

April 27, 2003
Documentary Fails to Reflect Lifesaving Role of Drug for Patients Afflicted with Thalassemia, a Rare Blood Disease
LONDON, UK – True Vision’s documentary, Dying for Drugs, which aired on Channel 4 at 8:30 PM, tonight, misrepresented many elements of the development of Ferriprox® (deferiprone), a drug developed by Apotex Inc. for the treatment of a life-threatening condition-chronic iron overload...

March 4, 2003
Apotex Wins Key Battle Over Generic Paxil® - Court Victory on Hemihydrate Patent Clears Key Hurdle
WESTON, FLORIDA, U.S.A. – Apotex Corp. today praised a U.S. federal judge ruling that its generic version of Paxil® (paroxetine hydrochloride) does not infringe a patent held by GlaxoSmithKline. The ruling is a major step forward toward launch of Apotex’s generic version of GSK’s Paxil® as the decision is subject to appeal and other patents remain to be litigated...

January 8, 2003
First Generic of Cholesterol Reducing Drug Zocor® Gets Approval In Canada
TORONTO, ONTARIO, CANADA – Apotex Inc. announced that on December 21st, it received its approval by Health Canada to market Apo-Simvastatin, a generic version of Zocor®. Shipments have commenced to pharmacies. Simvastatin is a cholesterol lowering agent in the “statin” family of drugs. In 2002, Zocor® had sales of approximately $275 million in Canada and has been marketed exclusively by Merck Frosst since 1990...

2002 Archive

2001 Archive

2000 Archive